|
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Clinical research trials and Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer. Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer clinical trial. Participants oftentimes recieve the most expert healthcare available for their Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer  Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
For Condition: Colon Cancer,Esophageal Cancer,Rectal Cancer,Pancreatic Cancer,Gastric Cancer,adult primary liver cancer,Colorectal Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of oxaliplatin plus irinotecan in treating patients with previously treated metastatic gastrointestinal cancer that has not responded to previous treatment.
Details: OBJECTIVES: I. Determine the maximum tolerated dose (MTD) for the combination chemotherapy regimen of oxaliplatin plus irinotecan when both drugs are given once a week for four weeks, followed by a two week rest, in patients with metastatic gastrointestinal cancer. II. Evaluate the toxicities of this combination chemotherapy when administered in this manner. III. Determine the pharmacokinetics of platinum and irinotecan at the MTD for this combination chemotherapy in this patient population. PROTOCOL OUTLINE: This is a dose escalation study. Patients receive oxaliplatin IV over 120 minutes, immediately followed by irinotecan IV over 30 minutes, weekly for 4 weeks (days 1, 8, 15, and 22). Courses are repeated every 42 days. Treatment continues in the absence of unacceptable side effects or disease progression. Sequential dose escalation of oxaliplatin is followed by sequential dose escalation of irinotecan. Dose escalation in cohorts of 3-6 patients each continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxic effects. Patients are followed approximately every 2-3 months. PROJECTED ACCRUAL: A total of 2-36 patients will be accrued for this study within 18-36 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed metastatic gastrointestinal carcinoma - Measurable disease - No CNS metastases - No obstruction or partial obstruction of GI tract - No obstruction of genitourinary tract --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior cisplatin, oxaliplatin, nitrosoureas, or mitomycin C 1 or 2 prior chemotherapy regimens allowed (including irinotecan) - Endocrine therapy: Not specified - Radiotherapy: No prior radiation therapy to whole pelvis, 30% or greater of bone marrow, and site of measurable disease; At least 4 weeks since prior radiation therapy and recovered - Surgery: Not specified --Patient Characteristics-- - Age: 18 and over - Performance status: Karnofsky 70-100% - Life expectancy: Not specified - Hematopoietic: WBC at least 3,500/mm3; Neutrophil count at least 1,500/mm3; Platelet count at least 125,000/mm3 - Hepatic: Bilirubin less than 1.5 mg/dL - Renal: Creatinine no greater than 1.5 mg/dL - Cardiovascular: No uncontrolled high blood pressure, unstable angina, active congestive heart failure, myocardial infarction within prior 6 months, or serious uncontrolled cardiac arrhythmia - Neurological: No concurrent symptomatic peripheral sensory neuropathy - Other: No active or uncontrolled infection; Not pregnant or nursing; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
NancyKemeny, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000066452; MSKCC-98034,NCI-G98-1450
Study Start Date: April 1998
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003427
Other Gastric Cancer Studies:
1. Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
2. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
3. Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
4. Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
5. A Phase 2 Study of Single Agent EKB-569 in Subjects with Advanced Colorectal Cancer.
Related Studies:
Other Gastric Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
|
|
|
|
|
|
|
|
